The current status of S-100B as a biomarker in melanoma
- 30 April 2012
- journal article
- review article
- Published by Elsevier BV in European Journal of Surgical Oncology
- Vol. 38 (4), 281-285
- https://doi.org/10.1016/j.ejso.2011.12.005
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Plasma Markers for Identifying Patients with Metastatic MelanomaClinical Cancer Research, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The Calcium-binding Protein S100B Down-regulates p53 and Apoptosis in Malignant MelanomaJournal of Biological Chemistry, 2010
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus MacrometastasesJournal of Clinical Oncology, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma PatientsAnnals of Surgical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694Journal of Clinical Oncology, 2009